Synthesis and Preclinical Evaluation of an <sup>18</sup>F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [<sup>18</sup>F]SynVesT-2
Zhengxin Cai, Songye Li, Wenjie Zhang, Richard Pracitto, Xiaoai Wu, Evan Baum, Sjoerd J. Finnema, Daniel Holden, Takuya Toyonaga, Shu-fei Lin, Marcel Lindemann, Anupama Shirali, David Labaree, Jim Ropchan, Nabeel Nabulsi, Richard E. Carson, Yiyun Huang
Abstract
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer’s disease, Parkinson’s disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.